Belimumab for scleroderma, diffuse

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Dec 2024: Trial registered, NCT06716606
  2. 12 Dec 2024: Trial started, NCT06716606

The trials

NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

State
Under way
Phase
Phase 3
People
514 planned
Started
12 Dec 2024
Primary completion
27 Sep 2030
Arms
Participants receiving Belimumab
Results
None posted
  1. 4 Dec 2024: Trial registered
  2. 12 Dec 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Benlysta, Lymphostat-b.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.